Delivery Order SPE2DB20D3101-SPE2DB25FRTU3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package, valued at $1,036.29. This firm fixed-price delivery order, with an ultimate completion date of August 21, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,857.35 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of dapagliflozin 10 mg tablets in quantities of 30 units. The contract represents a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX). Performance will be completed by July 25, 2025, with fulfillment occurring at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a contract ceiling value of $10,763.89. This firm fixed-price delivery order, which reaches ultimate completion on August 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count) with a ceiling value of $5,275.63. This competitive, non-set-aside delivery order represents a firm fixed price transaction with an ultimate completion date of July 29, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dapagliflozin 5 mg tablets in quantities of 30 units, with a ceiling value of $8,774.89. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by August 20, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This competitive award, valued at approximately $45K, represents a firm fixed-price delivery order with an ultimate completion date of August 21, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a $5,346.26 delivery order to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a delivery order, indicating it is issued under a larger indefinite delivery contract (IDC) vehicle. The pharmaceutical product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count package) under a firm fixed-price contract valued at $1,722.16. This is a non-set-aside competitive award with an ultimate completion date of August 4, 2025, with performance to take place at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count units) valued at $1,605.86. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 20, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation and represents a routine pharmaceutical supply transaction...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package at a ceiling value of $1,333.77. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRTU3Delivery Order
The Defense Logistics Agency awarded a $27,531.60 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count units). This firm fixed-price contract, issued without set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The delivery order specifies a place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of August 29, 2025, reflecting the expedited nature of pharmaceutical supply chain deliveries to federal medical programs. This award is part of AmerisourceBergen's substantial pharmaceutical support relationship with the Department of Defense, whereby the company serves as a critical vendor for military healthcare systems and other federal agencies. The company's $999.999 billion IDC with DLA Troop Support Medical through December 2026 enables delivery of a comprehensive portfolio of pharmaceutical products and medical supplies supporting global military healthcare operations. The current dapagliflozin delivery order exemplifies the company's role in supplying specialized medications, including diabetes treatments, to support Defense Health Agency and other federal healthcare customers through DLA's medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.5k | 8/28/25 |